77 related articles for article (PubMed ID: 24772947)
21. Sonochemotherapy inhibits the adhesion, migration and invasion of human ovarian cancer cells with highly metastatic potential.
Zhou S; Yu T; Zhang J; Liu S; Huo Y; Zhang Y
Ultraschall Med; 2011 Jan; 32 Suppl 1():S14-20. PubMed ID: 20425685
[TBL] [Abstract][Full Text] [Related]
22. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Thomadaki H; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
[TBL] [Abstract][Full Text] [Related]
23. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
[TBL] [Abstract][Full Text] [Related]
24. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
25. Drug uptake enhancement using sonodynamic effects at 4 MHz--a potential application for micro-ultrasonic-Transducers.
Siu T; Jackson J; Burt H; Chiao M
IEEE Trans Biomed Eng; 2007 Jun; 54(6 Pt 2):1153-6. PubMed ID: 17549907
[TBL] [Abstract][Full Text] [Related]
26. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
27. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
28. [Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance].
Lu RQ; Sun M; Gao X; Guo L
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):176-81. PubMed ID: 22780969
[TBL] [Abstract][Full Text] [Related]
29. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
30. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Thomadaki H; Scorilas A
Biol Chem; 2008 Nov; 389(11):1427-34. PubMed ID: 18783338
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
32. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.
Rizvi I; Celli JP; Evans CL; Abu-Yousif AO; Muzikansky A; Pogue BW; Finkelstein D; Hasan T
Cancer Res; 2010 Nov; 70(22):9319-28. PubMed ID: 21062986
[TBL] [Abstract][Full Text] [Related]
33. Role of carbonate in the cytotoxicity of carboplatin.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2007 Jun; 20(6):896-904. PubMed ID: 17497898
[TBL] [Abstract][Full Text] [Related]
34. The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Cadron I; Van Gorp T; Mihalyi A; Luyten C; Drijkoningen K; Amant F; Leunen K; Vergote I
Gynecol Oncol; 2010 Jul; 118(1):64-8. PubMed ID: 20439112
[TBL] [Abstract][Full Text] [Related]
35. Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2.
Upadhyay AK; Singh S; Chhipa RR; Vijayakumar MV; Ajay AK; Bhat MK
Toxicol Appl Pharmacol; 2006 Oct; 216(2):177-85. PubMed ID: 16806341
[TBL] [Abstract][Full Text] [Related]
36. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro.
Bilir A; Altinoz MA; Attar E; Erkan M; Aydiner A
Neoplasma; 2002; 49(1):38-42. PubMed ID: 12044058
[TBL] [Abstract][Full Text] [Related]
37. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
[TBL] [Abstract][Full Text] [Related]
38. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy guidance of the drug sensitivity test in vitro in human laryngeal squamous cell carcinoma].
Zhang S; Kong W
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Aug; 20(15):711-3. PubMed ID: 17037023
[TBL] [Abstract][Full Text] [Related]
40. FAU regulates carboplatin resistance in ovarian cancer.
Moss EL; Mourtada-Maarabouni M; Pickard MR; Redman CW; Williams GT
Genes Chromosomes Cancer; 2010 Jan; 49(1):70-7. PubMed ID: 19830698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
